- Home
- SFNC vs GLPG Comparison
SFNC vs GLPG Comparison
Compare SFNC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFNC
- GLPG
- Stock Information
- Founded
- SFNC 1903
- GLPG 1999
- Country
- SFNC United States
- GLPG Belgium
- Employees
- SFNC N/A
- GLPG N/A
- Industry
- SFNC Major Banks
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- SFNC Finance
- GLPG Health Care
- Exchange
- SFNC Nasdaq
- GLPG Nasdaq
- Market Cap
- SFNC 2.6B
- GLPG 2.1B
- IPO Year
- SFNC N/A
- GLPG 2005
- Fundamental
- Price
- SFNC $18.07
- GLPG $31.38
- Analyst Decision
- SFNC Hold
- GLPG Hold
- Analyst Count
- SFNC 3
- GLPG 4
- Target Price
- SFNC $23.00
- GLPG $31.33
- AVG Volume (30 Days)
- SFNC 1.3M
- GLPG 212.8K
- Earning Date
- SFNC 10-16-2025
- GLPG 11-05-2025
- Dividend Yield
- SFNC 4.69%
- GLPG N/A
- EPS Growth
- SFNC N/A
- GLPG N/A
- EPS
- SFNC N/A
- GLPG N/A
- Revenue
- SFNC N/A
- GLPG $336,643,201.00
- Revenue This Year
- SFNC $27.12
- GLPG $1.77
- Revenue Next Year
- SFNC $7.58
- GLPG $0.44
- P/E Ratio
- SFNC N/A
- GLPG N/A
- Revenue Growth
- SFNC N/A
- GLPG 10.31
- 52 Week Low
- SFNC $17.00
- GLPG $22.36
- 52 Week High
- SFNC $25.56
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- SFNC 47.84
- GLPG 45.32
- Support Level
- SFNC $17.36
- GLPG $29.81
- Resistance Level
- SFNC $18.35
- GLPG $33.12
- Average True Range (ATR)
- SFNC 0.37
- GLPG 0.78
- MACD
- SFNC 0.13
- GLPG 0.13
- Stochastic Oscillator
- SFNC 78.16
- GLPG 48.07
About SFNC Simmons First National Corporation
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.